EISAI ANNOUNCES EXCLUSIVE IN-LICENSE OF ALL U.S. PROMOTIONAL RIGHTS FOR FRAGMIN

Eisai Inc. (Headquarters: Teaneck, Chairman and CEO: Hajime Shimizu), a U.S. pharmaceutical subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito), today announced an in-license agreement with Pfizer Inc for exclusive U.S. rights to promote Fragmin® (dalteparin sodium injection), an anti-coagulant. Eisai also will assume responsibility for post-marketing studies and product distribution, as well as book all U.S. sales. According to this agreement, Pfizer will transfer the New Drug Application for Fragmin® to Eisai for the duration of the deal.

Market Wire (http://www.marketwire.com/mw/release_html_b1?release_id=96460)